Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study

医学 呼出气一氧化氮 奥马佐单抗 哮喘 气道 耐火材料(行星科学) 内科学 乙酰甲胆碱 呼出气冷凝液 肺活量测定 免疫球蛋白E 麻醉 免疫学 呼吸道疾病 病理 肺结核 抗体 物理 天体生物学
作者
Tomoko Tajiri,Akio Niimi,Hisako Matsumoto,Isao Ito,Tsuyoshi Oguma,Kojiro Otsuka,Tomoshi Takeda,Hitoshi Nakaji,Hideki Inoue,Toshiyuki Iwata,Tadao Nagasaki,Yoshihiro Kanemitsu,Yumi Izuhara,Michiaki Mishima
出处
期刊:Annals of Allergy Asthma & Immunology [Elsevier]
卷期号:113 (4): 470-475.e2 被引量:76
标识
DOI:10.1016/j.anai.2014.06.004
摘要

Background Omalizumab, a humanized anti-IgE monoclonal antibody, is reportedly an effective treatment for severe allergic asthma. However, there have been few comprehensive analyses of its efficacy, including assessments of small airways or airway remodeling. Objective To comprehensively evaluate the efficacy of omalizumab, including its effects on small airways and airway remodeling, in adult patients with severe refractory asthma. Methods In this prospective, time-series, single-arm observational study, 31 adult patients with severe refractory asthma despite the use of multiple controller medications, including high-dose inhaled corticosteroids (1,432 ± 581 μg/d of fluticasone propionate equivalent), were enrolled. Clinical variables, including Asthma Quality of Life Questionnaire, asthma exacerbations, exhaled nitric oxide, pulmonary function, methacholine airway responsiveness, induced sputum, and chest computed tomogram, were assessed at baseline and after 16 and 48 weeks of treatment with omalizumab. Results Twenty-six of the 31 patients completed 48 weeks of treatment. For these patients, Asthma Quality of Life Questionnaire scores and peak expiratory flow values significantly and continuously improved throughout the 48 weeks (P < .001 for all comparisons). Unscheduled physician visits, asthma exacerbations requiring systemic corticosteroids, fractional exhaled nitric oxide at 50 mL/s and alveolar nitric oxide levels, sputum eosinophil proportions, and airway-wall thickness as assessed by computed tomography significantly decreased at 48 weeks (P < .05 for all comparisons). Conclusion Omalizumab was effective for adult patients with severe refractory asthma. Omalizumab may have anti-inflammatory effects on small airways and reverse airway remodeling. Trial registration UMIN000002389.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助左白易采纳,获得10
3秒前
8R60d8应助科研通管家采纳,获得10
3秒前
bkagyin应助科研通管家采纳,获得10
3秒前
共享精神应助科研通管家采纳,获得10
3秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
爆米花应助科研通管家采纳,获得10
4秒前
Lucas应助科研通管家采纳,获得10
4秒前
科研通AI2S应助科研通管家采纳,获得10
4秒前
4秒前
8R60d8应助科研通管家采纳,获得10
4秒前
5秒前
7秒前
7秒前
7秒前
Hello应助虚拟的绿蕊采纳,获得10
8秒前
easy发布了新的文献求助10
9秒前
10秒前
ZZ发布了新的文献求助30
11秒前
橘子海发布了新的文献求助10
12秒前
小丑完成签到,获得积分10
13秒前
you完成签到,获得积分10
15秒前
15秒前
耍酷的豪英完成签到,获得积分10
15秒前
calm完成签到,获得积分10
17秒前
17秒前
17秒前
20秒前
阔达的访风应助橘子海采纳,获得20
21秒前
21秒前
25秒前
cc发布了新的文献求助10
25秒前
26秒前
深情安青应助耍酷的豪英采纳,获得10
29秒前
Xenia完成签到,获得积分10
29秒前
cctv18应助luchong采纳,获得30
29秒前
酷波er应助easy采纳,获得10
30秒前
srf0602.发布了新的文献求助10
32秒前
左白易发布了新的文献求助10
33秒前
36秒前
36秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3247668
求助须知:如何正确求助?哪些是违规求助? 2890943
关于积分的说明 8265433
捐赠科研通 2559211
什么是DOI,文献DOI怎么找? 1387967
科研通“疑难数据库(出版商)”最低求助积分说明 650670
邀请新用户注册赠送积分活动 627505